Your browser doesn't support javascript.
loading
SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques.
Dalvie, Neil C; Tostanoski, Lisa H; Rodriguez-Aponte, Sergio A; Kaur, Kawaljit; Bajoria, Sakshi; Kumru, Ozan S; Martinot, Amanda J; Chandrashekar, Abishek; McMahan, Katherine; Mercado, Noe B; Yu, Jingyou; Chang, Aiquan; Giffin, Victoria M; Nampanya, Felix; Patel, Shivani; Bowman, Lesley; Naranjo, Christopher A; Yun, Dongsoo; Flinchbaugh, Zach; Pessaint, Laurent; Brown, Renita; Velasco, Jason; Teow, Elyse; Cook, Anthony; Andersen, Hanne; Lewis, Mark G; Camp, Danielle L; Silverman, Judith Maxwell; Nagar, Gaurav S; Rao, Harish D; Lothe, Rakesh R; Chandrasekharan, Rahul; Rajurkar, Meghraj P; Shaligram, Umesh S; Kleanthous, Harry; Joshi, Sangeeta B; Volkin, David B; Biswas, Sumi; Love, J Christopher; Barouch, Dan H.
Afiliação
  • Dalvie NC; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Tostanoski LH; The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Rodriguez-Aponte SA; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Kaur K; The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Bajoria S; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Kumru OS; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.
  • Martinot AJ; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.
  • Chandrashekar A; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.
  • McMahan K; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Mercado NB; Departments of Infectious Diseases and Global Health and Comparative Pathobiology, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA 01536, USA.
  • Yu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Chang A; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Giffin VM; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Nampanya F; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Patel S; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Bowman L; Harvard Medical School, Boston, MA 02115, USA.
  • Naranjo CA; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Yun D; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Flinchbaugh Z; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Pessaint L; SpyBiotech Limited, Oxford Business Park North, Oxford OX4 2JZ, UK.
  • Brown R; The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Velasco J; The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Teow E; Bioqual, Rockville, MD 20852, USA.
  • Cook A; Bioqual, Rockville, MD 20852, USA.
  • Andersen H; Bioqual, Rockville, MD 20852, USA.
  • Lewis MG; Bioqual, Rockville, MD 20852, USA.
  • Camp DL; Bioqual, Rockville, MD 20852, USA.
  • Silverman JM; Bioqual, Rockville, MD 20852, USA.
  • Nagar GS; Bioqual, Rockville, MD 20852, USA.
  • Rao HD; Bioqual, Rockville, MD 20852, USA.
  • Lothe RR; The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Chandrasekharan R; Bill and Melinda Gates Medical Research Institute, Cambridge, MA 02139, USA.
  • Rajurkar MP; Serum Institute of India Pvt. Ltd., Pune, India.
  • Shaligram US; Serum Institute of India Pvt. Ltd., Pune, India.
  • Kleanthous H; Serum Institute of India Pvt. Ltd., Pune, India.
  • Joshi SB; Serum Institute of India Pvt. Ltd., Pune, India.
  • Volkin DB; Serum Institute of India Pvt. Ltd., Pune, India.
  • Biswas S; Serum Institute of India Pvt. Ltd., Pune, India.
  • Love JC; Bill and Melinda Gates Foundation, Seattle, WA 98109, USA.
  • Barouch DH; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.
Sci Adv ; 8(11): eabl6015, 2022 Mar 18.
Article em En | MEDLINE | ID: mdl-35294244
ABSTRACT
Authorized vaccines against SARS-CoV-2 remain less available in low- and middle-income countries due to insufficient supply, high costs, and storage requirements. Global immunity could still benefit from new vaccines using widely available, safe adjuvants, such as alum and protein subunits, suited to low-cost production in existing manufacturing facilities. Here, a clinical-stage vaccine candidate comprising a SARS-CoV-2 receptor binding domain-hepatitis B surface antigen virus-like particle elicited protective immunity in cynomolgus macaques. Titers of neutralizing antibodies (>104) induced by this candidate were above the range of protection for other licensed vaccines in nonhuman primates. Including CpG 1018 did not significantly improve the immunological responses. Vaccinated animals challenged with SARS-CoV-2 showed reduced median viral loads in bronchoalveolar lavage (~3.4 log10) and nasal mucosa (~2.9 log10) versus sham controls. These data support the potential benefit of this design for a low-cost modular vaccine platform for SARS-CoV-2 and other variants of concern or betacoronaviruses.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article